Literature DB >> 14871846

Cullin 3 promotes proteasomal degradation of the topoisomerase I-DNA covalent complex.

Hua-Feng Zhang1, Akihiro Tomida, Ritsuko Koshimizu, Yasunari Ogiso, Shuhong Lei, Takashi Tsuruo.   

Abstract

DNA topoisomerase I (TOP1)-DNA covalent complexes are the initial lesions produced by antitumor camptothecins (CPTs). The TOP1-directed drugs stimulate degradation of TOP1 via the ubiquitin-proteasome pathway. We found that proteasome inhibition prevents degradation of DNA-bound TOP1 and sustains high levels of covalent complexes, thus enhancing CPT-induced cell death. Consistent with this, increased degradation of TOP1-DNA covalent complexes was seen in acquired CPT-resistant cells. We found that the resistant cells showed elevated expressions of Cul3, a member of the cullin family of E3 ubiquitin ligases. The reduction in Cul3 expression by small interfering RNA decreased degradation of TOP1-DNA covalent complexes. Conversely, Cul3 overexpression by stable transfection promoted covalent complex degradation and reduced CPT-induced cell death without affecting basal TOP1 expression levels. These results indicate that Cul3, by promoting proteasomal degradation of TOP1-DNA covalent complexes, becomes an important regulator for cellular CPT sensitivity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14871846     DOI: 10.1158/0008-5472.can-03-2858

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  Constitutive turnover of cyclin E by Cul3 maintains quiescence.

Authors:  Justina D McEvoy; Uta Kossatz; Nisar Malek; Jeffrey D Singer
Journal:  Mol Cell Biol       Date:  2007-03-05       Impact factor: 4.272

2.  Functional interactions of DNA topoisomerases with a human replication origin.

Authors:  Gulnara Abdurashidova; Sorina Radulescu; Oscar Sandoval; Sotir Zahariev; Miltcho B Danailov; Alexander Demidovich; Laura Santamaria; Giuseppe Biamonti; Silvano Riva; Arturo Falaschi
Journal:  EMBO J       Date:  2007-02-08       Impact factor: 11.598

3.  An interaction network of the mammalian COP9 signalosome identifies Dda1 as a core subunit of multiple Cul4-based E3 ligases.

Authors:  Michael Hans Olma; Marcia Roy; Thierry Le Bihan; Izabela Sumara; Sarah Maerki; Brett Larsen; Manfredo Quadroni; Matthias Peter; Mike Tyers; Lionel Pintard
Journal:  J Cell Sci       Date:  2009-04-01       Impact factor: 5.285

4.  Repair pathway for PARP-1 DNA-protein crosslinks.

Authors:  Rajendra Prasad; Julie K Horton; Da-Peng Dai; Samuel H Wilson
Journal:  DNA Repair (Amst)       Date:  2018-11-12

Review 5.  Drugging topoisomerases: lessons and challenges.

Authors:  Yves Pommier
Journal:  ACS Chem Biol       Date:  2013-01-04       Impact factor: 5.100

6.  ISG15 as a novel tumor biomarker for drug sensitivity.

Authors:  Shyamal D Desai; Laurence M Wood; Yu-Chen Tsai; Tao-Shih Hsieh; Jeffrey R Marks; Georgia L Scott; Beppino C Giovanella; Leroy F Liu
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

7.  RBX1/ROC1-SCF E3 ubiquitin ligase is required for mouse embryogenesis and cancer cell survival.

Authors:  Lijun Jia; Yi Sun
Journal:  Cell Div       Date:  2009-08-06       Impact factor: 5.130

8.  Tipin functions in the protection against topoisomerase I inhibitor.

Authors:  Yoshifumi Hosono; Takuya Abe; Masato Higuchi; Kosa Kajii; Shuichi Sakuraba; Shusuke Tada; Takemi Enomoto; Masayuki Seki
Journal:  J Biol Chem       Date:  2014-02-25       Impact factor: 5.157

9.  Topoisomerase IIβ deficiency enhances camptothecin-induced apoptosis.

Authors:  Ren-Kuo Lin; Chia-Wen Ho; Leroy F Liu; Yi Lisa Lyu
Journal:  J Biol Chem       Date:  2013-01-22       Impact factor: 5.157

10.  The E3 ubiquitin-ligase Bmi1/Ring1A controls the proteasomal degradation of Top2alpha cleavage complex - a potentially new drug target.

Authors:  Iris Alchanati; Carmit Teicher; Galit Cohen; Vivian Shemesh; Haim M Barr; Philippe Nakache; Danny Ben-Avraham; Anna Idelevich; Itzchak Angel; Nurit Livnah; Shmuel Tuvia; Yuval Reiss; Daniel Taglicht; Omri Erez
Journal:  PLoS One       Date:  2009-12-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.